TODD CAMPBELL LEE

INPATIENT CONSULTATION

My primary clinical practice is to provide expert emergency room and inpatient consultations in the areas of Infectious Diseases and General Internal Medicine at the Royal Victoria Hospital (Glen Campus of the McGill University Health Centre).  I also work occasionally on the ID service at the Montreal General Hospital.

OUTPATIENT CONSULTATION

I provide expert outpatient consultations in Infectious Diseases through my involvement with the Fellow's Clinic held weekly at the Royal Victoria Hospital. This clinic sees adult patients by referral only. 

While open to most secondary and tertiary care referrals, our growing area of expertise is in the management of endovascular infections, infections in patients with immunocompromise, and infections involving the endemic mycoses.

​

Referrals from physicians in Quebec can be made by fax 514-934-4404; for second opinions from out of province contact me via email.  Unfortunately, consultation is available only to patients who are residents of Canada outside of emergencies and refugee health.

OUR TEAM DOES RESEARCH IN SEVERAL AREAS INCLUDING:

• Clinical Trials in Infectious Diseases

• Observational Studies in Infectious Diseases

• Medication Safety

• Health Care Resource Use and Quality Improvement

My up to date list of indexed publications can be found here.

COVID-19

COVID-19 PEP / Pre-Emptive Therapy

This is a pragmatic randomized controlled trial which compares hydroxychloroquine to placebo for (a) post-exposure prophylaxis within 4 days and (b) proven symptomatic disease within 4 days of onset.  It is a partnership with the University of Minnesota's similar study in the USA and we are the lead Canadian site in a multi-province Canadian arm.  For more information www.covid-19research.ca

​

CATCO Trial

We are a site in the national CATCO trial which will compare supportive care to Lopinavir/ritonavir; hydroxychloroquine and (potentially) remdesivir for the treatment of inpatients hospitalized with COVID-19

MEDSAFER

MedSafer is a custom developed software application which identifies deprescribing opportunities by analyzing patient medical history and medication lists as compared to expert derived rules for safer prescribing in the elderly.

The CIHR sponsored MedSafer Randomized Controlled Trial involving medical inpatients in Canada is ongoing and details can be found at the MedSafer website.

​

MedSafer is also being studied in projects in Long Term Care Facilities in Ontario and New Brunswick funded by The Centre for Aging + Brain Health Innovation (CABHI).

​

A public facing beta-version for physicians, pharmacists and patients will be available soon on a limited basis.

DASH

This is a randomized controlled trial evaluating whether the addition of  daptomycin to an anti-staphylococcal penicillin or cephalosporin accelerates clearance of Staphylococcus aureus bacteremia.  The trial has been co-designed and run by several fellows in Infectious Diseases at McGill University with my support and mentorship.

​

The trial methodology is described in print here and it is registered registered here.  This trial is no longer recruiting and will be published "soon".

TAPER-V

This is a CIHR-funded randomized controlled trial which will be starting in 2019 at approximately 17 centers in Canada. We are determining if an intitial pulse-taper approach reduces recurrance at day 56  NCT04138706

CLOUDTRIALS

Cloudtrials is an innovative clinical trials platform which has been in development since 2016.  It allows for distributed low-cost pragmatic trials at the point of care.  It will serve as the backbone for TAPER-V but is currently not available for public use.

HI-TEC

Can a simple and inexpensive technology-assisted physical examination differentiate between cellulitis and non-infectious causes of skin redness?  The HI-TEC study seeks to see using blinded measurements and comparing to the gold standard of sub-specialist diagnosis.  This trial was co-designed and is run by an internal medicine resident and our Infectious Diseases Fellows. NCT03846635

SNAP - CANADA

We are proud to be a site in the SNAP-Canada arm of the international (Austrailian-led) Staphylococcus aureus Network Adaptive Platform Trial.

OTHER

Our group is excited to be participating in the BALANCE trial comparing 7 vs. 14 days of therapy for bacteremia in ICU patients.

​

We are also excited to be participating in the PETERPEN trial comparing meropenem to piparacillin-tazobactam in ceftriaxone resistant E. coli and Klebsiella pneumoniae bactereamia.

​

We are collaborating on a study looking at fecal microbiota transplant to eradicate carriage of antibiotic resistant organisms

​

We are collaborating on a study evaluating whether fecal filtrate can be as successful as fecal microbiota transplant at preventing recurrent CDI.

​

We are collaborating on a study looking at whether universal screening and isolation of patients for C. difficile on admission will prevent nosocomial CDI.

​

Finally, we have some really exciting things going on in the clinical microbiology lab including combination beta-lactam therapy for carbapenem resistant organisms.

CONTACT ME

Please do not send me confidential health information via email.

I am sorry but I cannot answer patient questions for those not under my care.

​

Please note also that I generally do not meet with representatives of the pharmaceutical or device industries.

No solicitation, thank you!

Todd C. Lee
1001 Boulevard Décarie Room E5-1820

Montréal, Québec, Canada

H4A 3J1

Clinic: Room D2-4110 (514)934-1934 x 31611

todd.lee {at} mcgill.ca